by Stephanie Reid, MD FRCPC
November 18, 2026
Primary biliary cholangitis (PBC) is a long-lasting autoimmune disease in which the immune system slowly destroys the small bile ducts inside the liver. It is not cancer. Without treatment, the damage can lead to liver scarring over many years. With treatment, most people with PBC have a normal or near-normal life expectancy.
This article explains what primary biliary cholangitis is, how it is diagnosed, and what pathologists look for when they examine a liver biopsy. It also explains the stage in your report and the treatments now available. PBC was previously called primary biliary cirrhosis. The name was changed because cirrhosis is only a feature of advanced disease, and many people with PBC never reach that stage.
The liver makes bile, a fluid that helps digest fat and carries waste out of the body. Bile travels from the liver cells through a branching network of tubes called bile ducts. The smallest ducts sit in the portal tracts, the small areas where blood enters the liver and bile leaves it.
In primary biliary cholangitis, immune cells attack the cells lining these small bile ducts. Cholangitis means inflammation of the bile ducts. As the ducts are destroyed, bile backs up into the liver, a condition called cholestasis. Over time, the trapped bile and ongoing inflammation can cause scarring, called fibrosis.
Primary biliary cholangitis is an autoimmune disease. Its exact cause is not known. It likely develops when a person with certain inherited immune system genes is exposed to an environmental trigger. It is not contagious and is not caused by alcohol or diet.
People with PBC are more likely to have other autoimmune conditions. Examples include Sjögren syndrome, which causes dry eyes and mouth, systemic sclerosis, and celiac disease.
Primary biliary cholangitis mainly affects women, who make up about nine out of every ten people with the disease. It is usually diagnosed between the ages of 40 and 60 and is rare in children. It affects about 1 in 10,000 people. In Canada, outside Quebec, about 17,000 people are living with PBC.
Many people with primary biliary cholangitis have no symptoms when it is first found. The disease is often discovered because a routine liver blood test panel shows a raised alkaline phosphatase. When symptoms occur, the most common are:
In advanced disease, people may develop yellowing of the skin and eyes (jaundice) and complications of cirrhosis. PBC can also cause bone thinning and high cholesterol.
Most people with primary biliary cholangitis are diagnosed with blood tests alone. Doctors look for two main findings:
When both are present, and no other cause is found, doctors can usually diagnose the condition without a biopsy. An ultrasound is often done to make sure the larger bile ducts are not blocked.
A liver biopsy is done when the blood tests are not typical. Examples include people without antimitochondrial antibodies and people who may also have autoimmune hepatitis. A biopsy can also show how much scarring is present.
When a pathologist examines a liver biopsy for primary biliary cholangitis, they focus on the small bile ducts in the portal tracts. The changes are often patchy, so not every portal tract looks the same. Your report may describe some or all of the following features:
Some biopsies also show interface hepatitis, in which inflammation spills out of the portal tracts into the nearby liver cells. When this change is marked, the pathologist may comment that features of autoimmune hepatitis are also present. Doctors call this an overlap or variant condition.
The pathologist will also look for features of other diseases that affect the bile ducts. The most important is primary sclerosing cholangitis, which usually affects larger ducts and causes onion-skin scarring around them.
The stage describes how far the disease has progressed in the biopsy. The two most widely used systems, from Ludwig and from Scheuer, divide primary biliary cholangitis into four stages:
Some pathologists use the Nakanuma system instead. It adds separate scores for fibrosis, bile duct loss, and chronic cholestasis to give a stage, and it grades inflammation separately. Because PBC is patchy, different parts of the same liver can be at different stages. A small biopsy may therefore underestimate or overestimate the stage.
The outlook for primary biliary cholangitis has improved greatly with treatment. A large international study followed people treated with ursodeoxycholic acid. Those whose liver tests became normal did as well as, or better than, people of the same age and sex without PBC. About 20% to 40% of people do not respond well enough to ursodeoxycholic acid alone. These people have a higher risk of the disease progressing and are offered additional treatment.
People with PBC have a small increased risk of hepatocellular carcinoma, a type of liver cancer. In one Dutch study of treated patients, about 0.2% developed liver cancer each year. The risk is higher in men, in people with cirrhosis, and in people who do not respond to treatment.
After a diagnosis of primary biliary cholangitis, treatment usually starts right away and continues for life. A hepatologist, a doctor who specializes in the liver, often leads care.
Two newer medications are approved for people who do not respond to UDCA or cannot tolerate it. Both are taken by mouth, usually together with UDCA.
These approvals are based on improvements in alkaline phosphatase and other blood tests. Studies to confirm whether they prevent cirrhosis and improve survival are still underway.
An older second-line medication, obeticholic acid, is no longer available in some countries. The European Medicines Agency revoked its authorization in August 2024. It was withdrawn from the US market in September 2025 at the FDA’s request because of concerns about serious liver injury. A Canadian drug review published in 2026 still listed it among treatments used in Canada. If you take obeticholic acid, ask your doctor whether you should continue it.
🔍 Search MyPathologyReport
Type what you see on your report — for example a diagnosis or test name